Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors.
Human rhinovirus (HRV) is the most important etiologic agent causing common colds. No effective anti-HRV agents are currently available. In this paper we describe the synthesis and the evaluation of novel chloropyridazine derivatives (compounds 5a-g) as potent human rhinovirus (HRV) capsid-binding inhibitors. Results showed that compound 5e and 5f exhibited effective anti-HRV activity against HRV-2 and HRV-14. In addition, compound 5e and 5f showed lower cytotoxicity than Pirodavir.
Fan
Shi-Yong
SY
Beijing Institute of Pharmacology and Toxicology, 27 Taiping Road, Beijing 100850, China.
Zheng
Zhi-Bing
ZB
Mi
Chun-Lai
CL
Zhou
Xin-Bo
XB
Yan
Hui
H
Gong
Ze-Hui
ZH
Li
Song
S
D000998:Antiviral Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D036022:Capsid Proteins / Q000037:antagonists & inhibitors*; D003139:Common Cold / Q000188:drug therapy; D006801:Humans; D011724:Pyridazines / Q000138:chemical synthesis* / Q000494:pharmacology; D012229:Rhinovirus / Q000187:drug effects*; D013329:Structure-Activity Relationship
D000998:Antiviral Agents; D036022:Capsid Proteins; D011724:Pyridazines; C062482:pyridazine